FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to medicine, namely urology, and can be used for treating advanced prostate cancer in male individuals. That is ensured by administering a therapeutically effective amount of a compound of formula IV or its isomer, a pharmaceutically acceptable salt, a pharmaceutical product, a polymorph, a hydrate or any combination thereof
.
EFFECT: method provides treating effectively, inhibiting, reducing an incidence, relieving a severity or inhibiting advanced prostate cancer, as well as conducting the palliative treatment of advanced prostate cancer.
12 cl, 21 ex, 20 tbl, 23 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| SARM COMPOUNDS AND METHODS OF THEIR APPLICATION | 2011 |
|
RU2571421C2 |
| DEGARELIX THERAPY OF METASTATIC STAGE OF PROSTATE CANCER | 2009 |
|
RU2504394C2 |
| 1,2,4-OXADIAZOLE DERIVATIVES OF DESOXYCHOLIC ACID, EXHIBITING PROSTATE-PROTECTIVE EFFECT, HYPOCHOLESTEROLEMIC AND ANTI-INFLAMMATORY ACTIVITY | 2020 |
|
RU2750488C1 |
| METHOD OF TREATING PROSTATE CANCER WITH DEGARELIX THAT IS GONADOTROPIN-RELEASING HORMONE (GnRH) ANTAGONIST | 2009 |
|
RU2504393C2 |
| SELECTIVE ANDROGEN RECEPTOR DESTROYING AGENTS (SARD) AND METHODS OF USING THEREOF | 2016 |
|
RU2724103C2 |
| BISAMIDE DERIVATIVE OF DICARBOXYLIC ACID AS AGENT STIMULATING TISSUE REGENERATION AND RESTORATION OF REDUCED FUNCTIONS OF TISSUES | 2016 |
|
RU2727142C2 |
| METHODS OF TREATING UROLOGICAL DISORDERS USING SELECTIVE ANDROGEN RECEPTOR MODULATORS | 2015 |
|
RU2691652C2 |
| ANDROGEN RECEPTOR SELECTIVE DESTROYING (SARD) LIGANDS AND METHODS OF THEIR USE | 2017 |
|
RU2795431C2 |
| COMPOSITION FOR TREATING PROSTATE CANCER | 2010 |
|
RU2536245C2 |
| SELECTIVE ANDROGEN RECEPTOR DESTROYING (SARD) LIGANDS AND METHODS OF USING THEM | 2016 |
|
RU2689988C2 |
